iAnthus Capital Holdings, Inc.

DB:2IA Stock Report

Market Cap: €22.2m

iAnthus Capital Holdings Past Earnings Performance

Past criteria checks 0/6

iAnthus Capital Holdings has been growing earnings at an average annual rate of 20.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.9% per year.

Key information

20.3%

Earnings growth rate

59.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate8.9%
Return on equityn/a
Net Margin-32.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How iAnthus Capital Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2IA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24165-54740
30 Jun 24168-62730
31 Mar 24163-72770
31 Dec 23158-77780
30 Sep 23155-102730
30 Jun 23152-104810
31 Mar 23157-4581090
31 Dec 22163-4491140
30 Sep 22172-4331200
30 Jun 22182-4261210
31 Mar 22193-68970
31 Dec 21202-77970
30 Sep 21201-77860
30 Jun 21193-87870
31 Mar 21173-96870
31 Dec 20152-313920
30 Sep 20133-547950
30 Jun 20115-5341030
31 Mar 2099-5191080
31 Dec 1978-305950
30 Sep 1953-61850
30 Jun 1932-58610
31 Mar 1913-84430
31 Dec 183-62350
30 Sep 180-53270
30 Jun 180-45220
31 Mar 180-12140
31 Dec 170-14100
30 Sep 172-880
30 Jun 171-870
31 Mar 171-650
31 Dec 160-540
30 Sep 160-440
31 Dec 150-110

Quality Earnings: 2IA is currently unprofitable.

Growing Profit Margin: 2IA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2IA is unprofitable, but has reduced losses over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare 2IA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2IA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: 2IA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 18:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iAnthus Capital Holdings, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell StanleyBeacon Securities Limited
Nikolaas FaesBryan Garnier & Co
null nullCanaccord Genuity